BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fujirebio Diagnostics, Inc. Appoints Grady Barnes as Chief Scientific Officer


3/23/2009 10:45:14 AM

MALVERN, Pa., March 23 /PRNewswire/ -- Fujirebio Diagnostics, Inc., the premier cancer diagnostics company and the industry leader in cancer biomarker assays, today announced the appointment of Grady Barnes, Ph.D. as Chief Scientific Officer. Dr. Barnes comes to Fujirebio Diagnostics with 25 years of diagnostics experience. He has held various positions at Abbott and Meridian Bioscience, most recently as Vice President of Research & Development at Meridian Bioscience.

As Chief Scientific Officer, Dr. Barnes will be responsible for all scientific affairs including research and development, product development, process engineering and clinical and regulatory affairs. He will also assist in the selection of new product candidates and licensing opportunities for Fujirebio Diagnostics products.

"Dr. Barnes' extensive experience in diagnostics will be vital to sustaining Fujirebio Diagnostics' growth," says Paul Touhey, President and CEO of Fujirebio Diagnostics. "His expertise will support the growth and acceptance of biomarker assays in ovarian cancer, such as HE4, and help Fujirebio Diagnostics identify additional promising biomarkers in oncology."

Barnes received a Bachelor of Arts degree in natural sciences from Johns Hopkins University, and his Ph.D. in biochemistry from Florida State University. He has directed the commercialization of over 50 products, including diagnostic assay kits, hardware and software.

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings, Inc., in Japan, set up in July 2005 to combine Fujirebio Inc., the leading in-vitro diagnostics company, and SRL, Inc., the top provider of clinical laboratory testing services in Japan. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call

610-240-3800 or visit www.fdi.com.

CONTACT: Maureen Miller of JFK Communications, Inc., +1-609-514-5117,
Mobile: +1-908-268-5113, for Fujirebio Diagnostics, Inc.

Web site: http://www.fdi.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES